$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000117887919000024 Filed on February 28, 2019

Income Statement

Concept	2019 Q1	2018	2017 Q4
Revenue	$34.05M	$91.25M	$14.73M
YoY Change	103.92%	147.08%	420.49%
Cost Of Revenue	$4.055M	$14.40M	$2.610M
YoY Change	55.07%	130.98%	432.65%
Gross Profit	$29.99M	$76.84M	$12.12M
YoY Change	112.99%	150.35%	417.95%
Gross Profit Margin	88.09%	84.21%	82.28%
Selling, General & Admin	$44.30M	$127.2M	$28.58M
YoY Change	61.71%	43.45%	53.0%
% of Gross Profit	147.72%	165.54%	235.81%
Research & Development	$64.59M	$270.9M	$45.81M
YoY Change	58.32%	81.44%	49.56%
% of Gross Profit	215.37%	352.55%	377.97%
Depreciation & Amortization	$991.0K	$4.216M	$1.100M
YoY Change	2.27%	17.34%	22.22%
% of Gross Profit	3.3%	5.49%	9.08%
Operating Expenses	$111.3M	$405.6M	$79.80M
YoY Change	58.36%	-14.19%	67.12%
Operating Profit	-$81.28M	-$328.8M	-$67.68M
YoY Change	44.67%	-25.61%	49.04%
Interest Expense	$6.454M	$22.40M	-$3.030M
YoY Change	43.81%	29.94%	119.57%
% of Operating Profit
Other Income/Expense, Net	$1.086M	-$5.632M	$950.0K
YoY Change	-60.71%	-193.74%	-159.75%
Pretax Income	-$120.1M	-$349.1M	-$69.75M
YoY Change	134.14%	-22.27%	13.08%
Income Tax	$168.0K	-$94.00K	$2.160M
% Of Pretax Income
Net Earnings	-$120.3M	-$349.0M	-$69.21M
YoY Change	141.0%	22.88%	18.0%
Net Earnings / Revenue	-353.34%	-382.48%	-469.84%
Basic Earnings Per Share
Diluted Earnings Per Share	-$563.4K	-$1.878M	-$415.6K
COMMON SHARES
Basic Shares Outstanding	223.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$438.3M	$504.2M	$358.6M
YoY Change	-22.08%	40.6%	8.54%
Cash & Equivalents	$96.35M	$79.70M	$49.06M
Short-Term Investments	$342.0M	$424.4M	$309.5M
Other Short-Term Assets	$13.60M	$16.60M	$19.30M
YoY Change	28.3%	-13.99%	286.0%
Inventory	$8.167M	$8.400M	$4.623M
Prepaid Expenses
Receivables	$22.96M	$22.00M	$9.464M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$483.0M	$551.1M	$392.0M
YoY Change	-18.4%	40.59%	15.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.29M	$11.40M	$9.062M
YoY Change	49.28%	25.27%	-7.53%
Goodwill	$197.8M		$197.8M
YoY Change
Intangibles	$23.00M		$23.00M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.27M	$6.700M	$5.200M
YoY Change	101.16%	28.85%	108.0%
Total Long-Term Assets	$281.7M	$238.9M	$235.1M
YoY Change	1.32%	1.66%	-66.26%
TOTAL ASSETS
Total Short-Term Assets	$483.0M	$551.1M	$392.0M
Total Long-Term Assets	$281.7M	$238.9M	$235.1M
Total Assets	$764.7M	$790.0M	$627.0M
YoY Change	-12.1%	26.0%	-39.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$60.60M	$6.600M	$7.867M
YoY Change	38.67%	-16.46%	-80.81%
Accrued Expenses	$2.500M	$36.20M
YoY Change		-2.69%
Deferred Revenue			$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$65.87M	$86.10M	$70.04M
YoY Change	-53.18%	23.0%	-36.9%
LONG-TERM LIABILITIES
Long-Term Debt	$168.8M	$321.7M	$164.2M
YoY Change	1.2%	95.92%	6.28%
Other Long-Term Liabilities	$3.609M	$32.70M	$2.346M
YoY Change	-89.54%	-2.39%	-99.01%
Total Long-Term Liabilities	$3.609M	$354.4M	$2.346M
YoY Change	-98.21%	79.26%	-99.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$65.87M	$86.10M	$70.04M
Total Long-Term Liabilities	$3.609M	$354.4M	$2.346M
Total Liabilities	$313.0M	$447.0M	$274.2M
YoY Change	-10.15%	63.02%	-59.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.533B		-$1.064B
YoY Change	-400236.03%
Common Stock	$1.973B		$1.402B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$451.7M	$342.9M	$352.9M
YoY Change
Total Liabilities & Shareholders Equity	$764.7M	$790.0M	$627.0M
YoY Change	-12.1%	26.0%	-39.52%

Cashflow Statement

Concept	2019 Q1	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$120.3M	-$349.0M	-$69.21M
YoY Change	141.0%	22.88%	18.0%
Depreciation, Depletion And Amortization	$991.0K	$4.216M	$1.100M
YoY Change	2.27%	17.34%	22.22%
Cash From Operating Activities	-$78.55M	-$300.0M	-$73.04M
YoY Change	58.61%	40.37%	131.14%
INVESTING ACTIVITIES
Capital Expenditures	$2.944M	$6.308M	-$1.130M
YoY Change	259.46%	39.37%	162.79%
Acquisitions
YoY Change
Other Investing Activities	$83.01M	-$114.9M	$52.66M
YoY Change	-145.67%	-31.09%	47.22%
Cash From Investing Activities	$80.07M	-$121.2M	$51.54M
YoY Change	-143.85%	-29.22%	45.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$294.6M
YoY Change	-100.0%	21.21%
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	$17.38M	$450.8M	6.860M
YoY Change	-94.14%	82.18%	-95.44%
NET CHANGE
Cash From Operating Activities	-$78.55M	-$300.0M	-73.04M
Cash From Investing Activities	$80.07M	-$121.2M	51.54M
Cash From Financing Activities	$17.38M	$450.8M	6.860M
Net Change In Cash	$16.55M	$31.14M	-14.64M
YoY Change	-74.66%	-122.87%	-109.5%
FREE CASH FLOW
Cash From Operating Activities	-$78.55M	-$300.0M	-$73.04M
Capital Expenditures	$2.944M	$6.308M	-$1.130M
Free Cash Flow	-$81.49M	-$306.3M	-$71.91M
YoY Change	61.88%	40.35%	130.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	465427000	USD
CY2017Q4	fold	Accrued Contract Manufacturing And Contract Research Costs Current AccruedContractManufacturingAndContractResearchCostsCurrent	4632000	USD
CY2018Q4	fold	Accrued Contract Manufacturing And Contract Research Costs Current AccruedContractManufacturingAndContractResearchCostsCurrent	5890000	USD
CY2017Q4	fold	Accrued Facility Costs Current AccruedFacilityCostsCurrent	1665000	USD
CY2018Q4	fold	Accrued Facility Costs Current AccruedFacilityCostsCurrent	2102000	USD
CY2017Q4	fold	Accrued Program Fees AccruedProgramFees	5707000	USD
CY2018Q4	fold	Accrued Program Fees AccruedProgramFees	16674000	USD
CY2017Q4	fold	Accrued Sales Rebates And Chargebacks Current AccruedSalesRebatesAndChargebacksCurrent	1957000	USD
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	223708827	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	2325721562	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS, INC.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018Q4	fold	Accrued Sales Rebates And Chargebacks Current AccruedSalesRebatesAndChargebacksCurrent	3636000	USD
CY2018	fold	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature Capped Call AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureCappedCall	2739000	USD
CY2016	fold	Adjustments To Additional Paid In Capital Premiums Paid For Capped Call Confirmations AdjustmentsToAdditionalPaidInCapitalPremiumsPaidForCappedCallConfirmations	-13450000	USD
CY2016	fold	Adjustments To Additional Paid In Capital Receivable From Investor AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor	932000	USD
CY2017Q4	fold	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill Before Impairment Testing BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillBeforeImpairmentTesting	486700000	USD
CY2016	fold	Capital Lease Obligations Incurred Funded By Capital Lease Borrowings CapitalLeaseObligationsIncurredFundedByCapitalLeaseBorrowings	944000	USD
CY2017	fold	Capital Lease Obligations Incurred Funded By Capital Lease Borrowings CapitalLeaseObligationsIncurredFundedByCapitalLeaseBorrowings	0	USD
CY2018	fold	Capital Lease Obligations Incurred Funded By Capital Lease Borrowings CapitalLeaseObligationsIncurredFundedByCapitalLeaseBorrowings	208000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	358998000	USD
CY2018Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	504579000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2018Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	437000	USD
CY2018Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	438000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	358562000	USD
CY2018Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	504152000	USD
CY2017Q4	fold	Common Stock Voting Rights For Each Share Held CommonStockVotingRightsForEachShareHeld	1	vote
CY2016	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	6115000	USD
CY2017	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	0	USD
CY2018	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	0	USD
CY2017Q4	fold	Deferred Tax Assets Intellectual Property DeferredTaxAssetsIntellectualProperty	44573000	USD
CY2018Q4	fold	Deferred Tax Assets Intellectual Property DeferredTaxAssetsIntellectualProperty	48339000	USD
CY2017Q4	fold	Deferred Tax Assets Interest Carryforward Limitation DeferredTaxAssetsInterestCarryforwardLimitation	0	USD
CY2018Q4	fold	Deferred Tax Assets Interest Carryforward Limitation DeferredTaxAssetsInterestCarryforwardLimitation	1032000	USD
CY2017Q4	fold	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	264088000	USD
CY2018Q4	fold	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	356540000	USD
CY2017Q4	fold	Deferred Tax Assets Non Cash Stock Issue Non Current DeferredTaxAssetsNonCashStockIssueNonCurrent	10751000	USD
CY2018Q4	fold	Deferred Tax Assets Non Cash Stock Issue Non Current DeferredTaxAssetsNonCashStockIssueNonCurrent	16850000	USD
CY2017Q4	fold	Deferred Tax Liabilities Advanced Research And Development Payments DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments	3069000	USD
CY2018Q4	fold	Deferred Tax Liabilities Advanced Research And Development Payments DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments	2103000	USD
CY2017Q4	fold	Deferred Tax Liabilities Business Acquisition DeferredTaxLiabilitiesBusinessAcquisition	6465000	USD
CY2018Q4	fold	Deferred Tax Liabilities Business Acquisition DeferredTaxLiabilitiesBusinessAcquisition	6465000	USD
CY2017Q4	fold	Deferred Tax Liabilities Convertible Notes DeferredTaxLiabilitiesConvertibleNotes	18991000	USD
CY2018Q4	fold	Deferred Tax Liabilities Convertible Notes DeferredTaxLiabilitiesConvertibleNotes	16666000	USD
CY2017Q4	fold	Deferred Tax Liabilities Royalty Payable DeferredTaxLiabilitiesRoyaltyPayable	44573000	USD
CY2018Q4	fold	Deferred Tax Liabilities Royalty Payable DeferredTaxLiabilitiesRoyaltyPayable	48339000	USD
CY2016	fold	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration	0.00
CY2017	fold	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration	0.18
CY2018	fold	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration	-0.01
CY2016	fold	Effective Income Tax Rate Reconciliation Impact Of2017 Act Percent EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent	0.00
CY2017	fold	Effective Income Tax Rate Reconciliation Impact Of2017 Act Percent EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent	-0.27
CY2018	fold	Effective Income Tax Rate Reconciliation Impact Of2017 Act Percent EffectiveIncomeTaxRateReconciliationImpactOf2017ActPercent	0.00
CY2018	fold	Foreign And State Income Tax Expense Benefit ForeignAndStateIncomeTaxExpenseBenefit	-100000	USD
CY2016	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-3660000	USD
CY2017	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	5620000	USD
CY2018	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-3217000	USD
CY2017Q4	fold	Goodwill Acquired Before Impairment Testing GoodwillAcquiredBeforeImpairmentTesting	197800000	USD
CY2016	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	0	USD
CY2017	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-12600000	USD
CY2018	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-6250000	USD
CY2016	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	825000	USD
CY2017	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	720000	USD
CY2018	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	458000	USD
CY2017	fold	Milestone Payable Accrued During Period MilestonePayableAccruedDuringPeriod	0	USD
CY2018	fold	Milestone Payable Accrued During Period MilestonePayableAccruedDuringPeriod	9000000	USD
CY2016	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	-3742000	USD
CY2017	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	-167305000	USD
CY2018	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	0	USD
CY2018Q4	fold	Number Of Approved Medicines For Fabry Disease NumberOfApprovedMedicinesForFabryDisease	1	medicine
CY2018Q4	fold	Number Of Gene Therapy Programs NumberOfGeneTherapyPrograms	14	program
CY2018Q4	fold	Number Of Gene Therapy Programs NumberOfGeneTherapyPrograms	4	program
CY2018Q4	fold	Number Of Gene Therapy Programs For Batten Disease NumberOfGeneTherapyProgramsForBattenDisease	2	program
CY2018Q3	fold	Number Of Gene Therapy Programs For Neurologic Ls Ds Developed NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped	10	program
CY2018Q4	fold	Operating Leases Future Minimum Payments Due In Five Years And Thereafter OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter	13649000	USD
CY2016	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	5000000	USD
CY2017	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	10000000	USD
CY2018	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	USD
CY2016	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	1282000	USD
CY2017	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	1596000	USD
CY2018	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	2832000	USD
CY2016	fold	Premiums Paid For Capped Call Confirmations PremiumsPaidForCappedCallConfirmations	13450000	USD
CY2017	fold	Premiums Paid For Capped Call Confirmations PremiumsPaidForCappedCallConfirmations	0	USD
CY2018	fold	Premiums Paid For Capped Call Confirmations PremiumsPaidForCappedCallConfirmations	0	USD
CY2016	fold	Research Expense For Stock Issuance In Asset Acquisition ResearchExpenseForStockIssuanceInAssetAcquisition	4607000	USD
CY2017	fold	Research Expense For Stock Issuance In Asset Acquisition ResearchExpenseForStockIssuanceInAssetAcquisition	0	USD
CY2018	fold	Research Expense For Stock Issuance In Asset Acquisition ResearchExpenseForStockIssuanceInAssetAcquisition	0	USD
CY2018Q4	fold	Share Based Compensation Number Of Plans ShareBasedCompensationNumberOfPlans	3	program
CY2016	fold	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	7321000	USD
CY2016	fold	Stock Issued During Period Value At Market Offering StockIssuedDuringPeriodValueAtMarketOffering	97068000	USD
CY2016	fold	Stock Issued During Period Value Contingent Consideration StockIssuedDuringPeriodValueContingentConsideration	6115000	USD
CY2018	fold	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3617000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	53890000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	80625000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7867000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6606000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9464000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21962000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5845000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2276000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2529000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4463000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12515000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15671000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-436000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-427000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1659000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	495000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1400758000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1740061000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	88346000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-1282000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-1596000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-2832000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17504000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23101000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29260000	USD
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2689000	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9703000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	10976000	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	60232000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	61766000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63120000	shares
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q4	us-gaap	Assets Assets	627024000	USD
CY2018Q4	us-gaap	Assets Assets	789951000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	391965000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	551096000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	311700000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	427084000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	437000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	438000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	309938000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	424830000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	309502000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	424403000	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	6760000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-234322000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3300000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25400000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19700000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8400000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	17000000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	19700000	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	23000000	USD
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	23000000	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2017	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2018	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	106000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187026000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49060000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79749000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	49060000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	79749000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69485000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187413000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51237000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82375000	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	117928000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-136176000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31138000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-288144000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-346449000	USD
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	166989790	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189383924	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166989790	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189383924	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1721000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1942000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-197880000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9000000	USD
CY2017Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	164167000	USD
CY2018Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	175006000	USD
CY2016	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	833000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6236000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14404000	USD
CY2017Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2276000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-100000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	295100000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	403100000	USD
CY2017	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2018	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2017Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	2258000	USD
CY2018Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	2732000	USD
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	7750000	USD
CY2018Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	5500000	USD
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	14156000	USD
CY2018Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	10156000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1101000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-150015000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2709000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6465000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6465000	USD
CY2018	us-gaap	Depreciation Depreciation	4200000	USD
CY2018	us-gaap	Depreciation Depreciation	4216000	USD
CY2018Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	88300000	USD
CY2018Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	507400000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	3732000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.49
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	270600000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	270553000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	363005000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	43382000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	96509000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	363000000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6465000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6465000	USD
CY2016	us-gaap	Depreciation Depreciation	3242000	USD
CY2017	us-gaap	Depreciation Depreciation	3593000	USD
CY2017	us-gaap	Depreciation Depreciation	3600000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2645000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-17389000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	6158000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4401000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	337186000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	430113000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	221912000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	248398000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7328000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10852000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	3082000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.85
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.88
CY2016	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-131000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1326000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1518000	USD
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.02
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.37
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2700000	USD
CY2016	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-265000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	265000	USD
CY2018	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-2739000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.36
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.14
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.26
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.02
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.05
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.02
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.03
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.01
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.06
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.05
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.00
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.03
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.02
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.10
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19620000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21731000	USD
CY2016	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-13302000	USD
CY2017	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
CY2018	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-6760000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	234322000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-3300000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	269722000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	25400000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19700000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2739000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-17000	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	8000	USD
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-59000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13302000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	197800000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	197800000	USD
CY2018	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2016	us-gaap	Gross Profit GrossProfit	4125000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3651000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	897000	USD
CY2017	us-gaap	Gross Profit GrossProfit	30694000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	313000	USD
CY2018	us-gaap	Gross Profit GrossProfit	76841000	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4189000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-174913000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-440696000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-309183000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-203781000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-449121000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-349089000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-28868000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8425000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-39906000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3739000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-165119000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7131000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12563000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	17115000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1419000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7725000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13294000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4205000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	970000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	729000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1039000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	394000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	15329000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2488000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2016	us-gaap	Interest Expense InterestExpense	5398000	USD
CY2017	us-gaap	Interest Expense InterestExpense	17240000	USD
CY2018	us-gaap	Interest Expense InterestExpense	22402000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	2990000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	7424000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	7500000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	780000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3614000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	4623000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	8390000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2393000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1291000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3485000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	1602000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1450000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	186015000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	450775000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4509000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	472679000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	4096000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	10461000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	274174000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	447039000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	627024000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	789951000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	70040000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	86125000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	27658000	USD
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	22432000	USD
CY2018Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	309502000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	424403000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	272715000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	247434000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-171241000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121200000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-150147000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-213695000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-299955000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-200042000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-54992000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-48136000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-111666000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-69208000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-284002000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-49916000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-61833000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-159163000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-78083000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-348995000	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
CY2018	us-gaap	Operating Expenses OperatingExpenses	405618000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-181890000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-441985000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-328777000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	30887000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	6244000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	3371000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3560000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4063000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3500000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3900000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5700000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3755000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4058000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5200000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6683000	USD
CY2016	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	217000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-538000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	9000	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1945000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3604000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2537000	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	0	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2162000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4142000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2546000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2346000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2853000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4793000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6008000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5632000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	219932000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	490468000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	578394000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5951000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4526000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6308000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19316000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16592000	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	242536000	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	243000000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	97068000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	243037000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294600000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294584000	USD
CY2016	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	30000000	USD
CY2017	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	146596000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	221374000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	323753000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	463502000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3036000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16301000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	127200000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	17504000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	23101000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	29260000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	530035	shares
CY2017Q3	us-gaap	Share Price SharePrice	12.25
CY2018	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9144000	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3617000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	-200042000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-284002000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-348995000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21577000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27046000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9062000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11375000	USD
CY2016	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	193000	USD
CY2017	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	308000	USD
CY2018	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	334000	USD
CY2016	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	80000000	USD
CY2017	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
CY2016	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	104793000	USD
CY2017	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	149310000	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	270902000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	387000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2177000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2626000	USD
CY2016	us-gaap	Restructuring Charges RestructuringCharges	69000	USD
CY2017	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1063610000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1412222000	USD
CY2016	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4958000	USD
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	36930000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	91245000	USD
CY2017Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2018Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	146734000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71151000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	88671000	USD
CY2017Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	21122449	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	20239839	shares
CY2016	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	4607000	USD
CY2017Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	258800000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	243037000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	294583000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	17504000	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23101000	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29260000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3036000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16301000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9144000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	347834000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	360151000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	352850000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	342912000	USD
CY2017Q4	us-gaap	Trading Securities TradingSecurities	2200000	USD
CY2018Q4	us-gaap	Trading Securities TradingSecurities	2700000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	92400000	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	16076000	USD
CY2018Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13063000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134401588	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	153355144	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	185790021	shares
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">. The Company's accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> have arisen from product sales primarily in the EU and the United States. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates</font></div></div>

Files In Submission

Name	View Source	Status
0001178879-19-000024-index-headers.html	Edgar Link	pending
0001178879-19-000024-index.html	Edgar Link	pending
0001178879-19-000024.txt	Edgar Link	pending
0001178879-19-000024-xbrl.zip	Edgar Link	pending
amicus1231201810-k.htm	Edgar Link	pending
exhibit1048.htm	Edgar Link	pending
exhibit1049.htm	Edgar Link	pending
exhibit21.htm	Edgar Link	pending
exhibit231.htm	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
exhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-20181231.xml	Edgar Link	completed
fold-20181231.xsd	Edgar Link	pending
fold-20181231_cal.xml	Edgar Link	unprocessable
fold-20181231_def.xml	Edgar Link	unprocessable
fold-20181231_lab.xml	Edgar Link	unprocessable
fold-20181231_pre.xml	Edgar Link	unprocessable
item5graph.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2019 Q1 Form 10-K Financial Statement

#000117887919000024 Filed on February 28, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2019 Q1 Form 10-K Financial Statement

#000117887919000024 Filed on February 28, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold